Prostatypes USA-studie har nyligen presenterats i en vetenskaplig tidskrift.
Redeye provides its initial take on VEF’s Q4 2025 report, which featured continued NAV growth and re...
Cicor is an electronics manufacturing services (EMS) company with ~60 years of history, and we view ...
We expect Q4/25 to conclude a year of successful exits, putting VNV in a net cash position but with ...
Redeye gives an initial take on the news that IRLAB has entered into a collaboration with Biomia reg...
* Rottneros Q4 EBITDA of SEK -180m vs. our SEK -80m * Challenging markets for Rottneros and Arctic P...
* Q4'25 numbers due on 10 February at 07:45 CET * Expect new targets on the reporting day, more info...
Warm weather and the efficiency improvement programme should support profitability in Q4/25, we beli...
This morning SyntheticMR announced preliminary Q4 figures amid the ongoing rights issue.
* We forecast -3% EBITA growth in Q4'25 on a tough comp * 8% EBITA growth shows resilience in tough ...
* Q4 results due on Thursday, 5 February * Estimates up 2-4% organically, but neutralised by FX * Ma...
* Negative FX and calendar effects * We trim '25e-'27e EBIT by 2% * Trading at 9x NTM EV/EBIT FX an...
NextCell yesterday announced six-year follow-up data for ProTrans in type 1 diabetes, confirming tha...
Redeye shares its view on Sleep Cycle ahead of the Q4 report, due on February 4.
Redeye shares its view on Physitrack ahead of the preliminary trading update scheduled for 29 Januar...
Following a prolonged period of valuation pressure, the biotech sector regained momentum through 202...
The public release of Xspray’s CRL on openFDA yesterday triggered a double-digit intraday decline in...
This Monday, Perpetua Medical invited investors, media, and the public to virtually attend a Live St...
* Q4e: 4% organic sales growth, 11% adj. EBITA margin * We cut estimates on the downgraded outlook *...
* Wins a SEK 280m contract, starting in Q1'26 * Pure software delivery, supporting a stronger margin...
